Roche Pharmaceutical Development and Sales Overview

Alecensa Global sales CHFbn CER growth +16% Regional sales CER growth US +20% 1.2 1.0 000 0.4 0.8 0.6 0.2 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 1,127m • US: New patient share in 1L at around 70% • • EU: EU-5 new patient share in 1L at around 70% Japan: New patient share in 1L reaching >70% International: Strong growth driven by all regions CER-Constant Exchange Rates Europe +6% Japan +5% International +26% 161 Roche

View entire presentation